AAV-Mediated CRISPR/Cas Gene Editing of Retinal Cells in Vivo

Investigative Ophthalmology and Visual Science

Volumn 57, Issue 7, 2016, Pages 3470-3476

  Hung, Sandy S C ^a   Chrysostomou, Vicki ^a   Li, Fan ^a,b   Lim, Jeremiah K H ^a   Wang, Jiang Hui ^a   Powell, Joseph E ^c   Tu, Leilei ^a,d   Daniszewski, Maciej ^a   Lo, Camden ^e   Wong, Raymond C ^a   Crowston, Jonathan G ^a   Pébay, Alice ^a   King, Anna E ^f   Bui, Bang V ^a   Liu, Guei Sheung ^a   Hewitt, Alex W ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF TASMANIA   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d JINAN UNIVERSITY   (China)

^e MONASH UNIVERSITY   (Australia)

^f UNIVERSITY OF TASMANIA   (Australia)

Author keywords

Cas9; CRISPR; Gene editing; Guide RNA; In vivo

Indexed keywords

CRISPR ASSOCIATED PROTEIN; GUIDE RNA; PLASMID VECTOR; SINGLE GUIDE RNA; UNCLASSIFIED DRUG; YELLOW FLUORESCENT PROTEIN; BACTERIAL PROTEIN; PHOTOPROTEIN; YELLOW FLUORESCENT PROTEIN, BACTERIA;

3T3 CELL LINE; ADENO ASSOCIATED VIRUS 2; ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; B SCAN; CELL COUNTING; CONTROLLED STUDY; DNA MODIFICATION; ELECTRORETINOGRAPHY; FLUORESCENCE MICROSCOPE; GENE TARGETING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; INDEL ANALYSIS; MEDICAL PROCEDURES; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RETINA CELL; RETINA GANGLION CELL; RETINAL NERVE FIBER LAYER THICKNESS; RETINAL THICKNESS; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; STREPTOCOCCUS PYOGENES; TRANSGENIC MOUSE; VISION; ANIMAL; CELL CULTURE; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEAT; DEPENDOPARVOVIRUS; GENE EDITING; GENETIC ENGINEERING; GENETICS; INTRAOCULAR DRUG ADMINISTRATION; METABOLISM; PHYSIOLOGY; PLASMID; PROCEDURES; RETINA;

ANIMALS; BACTERIAL PROTEINS; CELLS, CULTURED; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEATS; DEPENDOVIRUS; ELECTRORETINOGRAPHY; GENE EDITING; GENETIC ENGINEERING; INJECTIONS, INTRAOCULAR; LUMINESCENT PROTEINS; MICE; MICE, TRANSGENIC; PLASMIDS; RETINA;

EID: 84976561853     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.16-19316     Document Type: Article

References (41)

1. Liew G, Michaelides M, Bunce C. A comparison of the causes of blindness certifications in England andWales in working age adults (16-64 years), 1999-2000 with 2009-2010. BMJ Open. 2014;4:e004015.
2. Chiang JP, Trzupek K. The current status of molecular diagnosis of inherited retinal dystrophies. Curr Opin Ophthalmol. 2015;26:346-351.
3. Hartong DT, Berson EL, Dryja TP. Retinitis pigmentosa. Lancet. 2006;368:1795-1809.
4. den Hollander AI. Omics in ophthalmology: advances in genomics and precision medicine for Leber congenital amaurosis and age-related macular degeneration. Invest Ophthalmol Vis Sci. 2016;57:1378-1387.
5. Tucker BA, Mullins RF, Stone EM. Stem cells for investigation and treatment of inherited retinal disease. Hum Mol Genet. 2014;23:R9-R16.
6. Bainbridge JW, Mehat MS, Sundaram V, et al. Long-term effect of gene therapy on Leber’s congenital amaurosis. N Engl J Med. 2015;372:1887-1897.
7. Jacobson SG, Cideciyan AV, Roman AJ, et al. Improvement and decline in vision with gene therapy in childhood blindness. N Engl J Med. 2015;372:1920-1926.
8. Trapani I, Toriello E, de Simone S, et al. Improved dual AAV vectors with reduced expression of truncated proteins are safe and effective in the retina of a mouse model of Stargardt disease. Hum Mol Genet. 2015;24:6811-6825.
9. Thompson DA, Ali RR, Banin E, et al. Advancing therapeutic strategies for inherited retinal degeneration: recommendations from the Monaciano Symposium. Invest Ophthalmol Vis Sci. 2015;56:918-931.
10. Daiger SP, Bowne SJ, Sullivan LS. Genes and mutations causing autosomal dominant retinitis pigmentosa. Cold Spring Harb Perspect Med. 2014;5i:a017129.
11. Mali P, Yang L, Esvelt KM, et al. RNA-guided human genome engineering via Cas9. Science. 2013;339:823-826.
12. Cong L, Ran FA, Cox D, et al. Multiplex genome engineering using CRISPR/Cas systems. Science. 2013;339:819-823.
13. Cox DB, Platt RJ, Zhang F. Therapeutic genome editing: prospects and challenges. Nat Med. 2015;21:121-131.
14. Yin H, Xue W, Chen S, et al. Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. Nat Biotechnol. 2014;32:551-553.
15. Long C, Amoasii L, Mireault AA, et al. Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy. Science. 2016;351:400-403.
16. Nelson CE, Hakim CH, Ousterout DG, et al. In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy. Science. 2016;351:403-407.
17. Tabebordbar M, Zhu K, Cheng JK, et al. In vivo gene editing in dystrophic mouse muscle and muscle stem cells. Science. 2016;351:407-411.
18. Wang S, Sengel C, Emerson MM, et al. A gene regulatory network controls the binary fate decision of rod and bipolar cells in the vertebrate retina. Dev Cell. 2014;30:513-527.
19. Bakondi B, Lv W, Lu B, et al. In vivo CRISPR/Cas9 gene editing corrects retinal dystrophy in the S334ter-3 rat model of autosomal dominant retinitis pigmentosa. Mol Ther. 2016;24: 556-563.
20. Feng G, Mellor RH, Bernstein M, et al. Imaging neuronal subsets in transgenic mice expressing multiple spectral variants of GFP. Neuron. 2000;28:41-51.
21. Ran FA, Hsu PD, Wright J, et al. Genome engineering using the CRISPR-Cas9 system. Nat Protoc. 2013;8:2281-2308.
22. Swiech L, Heidenreich M, Banerjee A, et al. In vivo interrogation of gene function in the mammalian brain using CRISPR-Cas9. Nat Biotechnol. 2015;33:102-106.
23. Xiao X, Li J, Samulski RJ. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol. 1998;72:2224-2232.
24. Grant CA, Ponnazhagan S, Wang XS, et al. Evaluation of recombinant adeno-associated virus as a gene transfer vector for the retina. Curr Eye Res. 1997;16:949-956.
25. Kohzaki K, Vingrys AJ, Bui BV. Early inner retinal dysfunction in streptozotocin-induced diabetic rats. Invest Ophthalmol Vis Sci. 2008;49:3595-3604.
26. Nguyen CT, Vingrys AJ, Wong VH, et al. Identifying cell class specific losses from serially generated electroretinogram components. Biomed Res Int. 2013;2013:796362.
27. Crowston JG, Kong YX, Trounce IA, et al. An acute intraocular pressure challenge to assess retinal ganglion cell injury and recovery in the mouse. Exp Eye Res. 2015;141:3-8.
28. Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods. 2012;9:671-675.
29. Macosko EZ, Basu A, Satija R, et al. Highly parallel genomewide expression profiling of individual cells using nanoliter droplets. Cell. 2015;161:1202-1214.
30. Cheng R, Peng J, Yan Y, et al. Efficient gene editing in adult mouse livers via adenoviral delivery of CRISPR/Cas9. FEBS Lett. 2014;588:3954-3958.
31. Zuris JA, Thompson DB, Shu Y, et al. Cationic lipid-mediated delivery of proteins enables efficient protein-based genome editing in vitro and in vivo. Nat Biotechnol. 2015;33:73-80.
32. Dow LE, Fisher J, O’Rourke KP, et al. Inducible in vivo genome editing with CRISPR-Cas9. Nat Biotechnol. 2015;33:390-394.
33. Slaymaker IM, Gao L, Zetsche B, et al. Rationally engineered Cas9 nucleases with improved specificity. Science. 2016;351: 84-88.
34. Kleinstiver BP, Pattanayak V, Prew MS, et al. High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide offtarget effects. Nature. 2016;529:490-495.
35. Dalkara D, Kolstad KD, Caporale N, et al. Inner limiting membrane barriers to AAV-mediated retinal transduction from the vitreous. Mol Ther. 2009;17:2096-2102.
36. Vandenberghe LH, Auricchio A. Novel adeno-associated viral vectors for retinal gene therapy. Gene Ther. 2012;19:162-168.
37. Dalkara D, Byrne LC, Klimczak RR, et al. In vivo-directed evolution of a new adeno-associated virus for therapeutic outer retinal gene delivery from the vitreous. Sci Transl Med. 2013;5:89ra76.
38. Wu Z, Yang H, Colosi P. Effect of genome size on AAV vector packaging. Mol Ther. 2010;18:80-86.
39. Ran FA, Cong L, Yan WX, et al. In vivo genome editing using Staphylococcus aureus Cas9. Nature. 2015;520:186-191.
40. Friedland AE, Baral R, Singhal P, et al. Characterization of Staphylococcus aureus Cas9: a smaller Cas9 for all-in-one adeno-associated virus delivery and paired nickase applications. Genome Biol. 2015;16:257.
41. Yang Y, Wang L, Bell P, et al. A dual AAV system enables the Cas9-mediated correction of a metabolic liver disease in newborn mice. Nat Biotechnol. 2016;34:334-338.